Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

• ClinicalTrials.gov Identifier: NCT03679676
• Recruitment Status: Recruiting
• First Posted: September 20, 2018
• Last Update Posted: November 28, 2022
• Sponsor: Stanford University
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID); Food Allergy Research & Education
• Information provided by (Responsible Party): R. Sharon Chinthrajah, Stanford University

Study Description

Brief Summary:

Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.

Condition or disease	Intervention/treatment	Phase
Hypersensitivity; Food Allergy; Hypersensitivity, Food; Peanut Hypersensitivity; Peanut Allergy	Drug: Omalizumab; Drug: Dupilumab; Other: Placebo	Phase 2

Detailed Description:

This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be peanut. The total population will be 110 participants, ages 4 to 55 years that present with a history of multiple food allergies of 2 or 3 different foods including peanut, food-allergen (FA)-specific IgE levels, and positive skin prick test (SPT).

Enrolled participants must react positively during DBPCFCs at or before the 300 mg (444 mg cumulative) dosing level of FA proteins of 2 or 3 allergens in which one must be a peanut.

There will be three study cohorts, all will be double blinded:

Cohort A (50 participants) will be treated with omalizumab for 8 weeks followed by 24 weeks of treatment with placebo. Cohort B (50 participants) will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab. Cohort C (10 participants) will be treated with placebo for 8 weeks followed by 24 weeks treatment with dupilumab. All cohorts will receive multifood allergen oral immunotherapy.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 110 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: This is a prospective Phase 2, single-center, multi-allergen OIT in participants with proven allergies to 2 or 3 different foods in which one must be peanut. Our intent to treat population will be 110 participants, ages 4 to 55 years with a history of multiple food allergies of 2 or 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the DBPCFCs at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes
• Actual Study Start Date: February 5, 2020
• Estimated Primary Completion Date: December 31, 2023
• Estimated Study Completion Date: December 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Cohort A: Omalizumab; Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with placebo	Drug: Omalizumab; Omalizumab is injected every 2 to 4 weeks; Other Name: Xolair; Other: Placebo; Placebo is injected every 2 to 4 weeks
Cohort B: Omalizumab/Dupilumab; Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab.	Drug: Omalizumab; Omalizumab is injected every 2 to 4 weeks; Other Name: Xolair; Drug: Dupilumab; Dupilumab is injected every 2 weeks combination, or placebo.; Other Name: Dupixent
Cohort C: Dupilumab; Participants will be treated with placebo for 8 weeks, followed by 24 weeks of treatment with dupilumab.	Drug: Dupilumab; Dupilumab is injected every 2 weeks combination, or placebo.; Other Name: Dupixent; Other: Placebo; Placebo is injected every 2 to 4 weeks

Outcome Measures

Primary Outcome Measures :

1. The success rates of passing a peanut Food Challenge (FC) [ Time Frame: 44 weeks ]
   Success is defined as passing a cumulative dose of >=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B.
2. The success rates of passing a FC to peanut and at least one other FA [ Time Frame: 44 weeks ]
   Success is defined as passing a cumulative dose of >=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B.
3. The success rates of passing a FC to peanut and two other FAs [ Time Frame: 44 weeks ]
   Success is defined as passing a cumulative dose of >=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B.

Secondary Outcome Measures :

1. Proportion of participants who successfully pass DBPCFCs to a cumulative dose of >=1,043 mg protein to 1, 2, or 3 FAs when applicable at week 44 [ Time Frame: 44 weeks ]
2. Proportion of participants who successfully pass DBPCFCs to a cumulative dose of ≥2,043 mg to 1, 2, or 3 FAs when applicable at week 32 [ Time Frame: 32 weeks ]
3. Proportion of participants who pass DBPCFCs for each FA at a cumulative dose of ≥1,043 mg, ≥2,043 mg, or ≥4,043 mg at week 32 and/or week 44. [ Time Frame: week 32 and/or 44 ]
4. Proportion of participants who have a 10-fold change in the cumulative tolerance dose for each FA at weeks 32 and/or week 44, compared to baseline [ Time Frame: Baseline and week 32 and/or 44 ]

Eligibility Criteria

• Ages Eligible for Study: 4 Years to 55 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age 4 through 55 years (inclusive).
• Clinical history of peanut allergy and 1 or 2 additional foods from the following foods: milk, almond, shellfish, fish, cashew, hazelnut, egg, walnut, sesame seeds, soy, and wheat. Allergy to milk and egg is defined as unable to tolerate both cooked and uncooked forms.
• Positive allergy test determined by:
• ImmunoCAP serum IgE level >4 kUA/L for each allergen within the past 12 months OR
• Skin prick test (SPT) ≥6 mm wheal diameter to each allergen.
• A clinical reaction during a DBPCFC to small doses of food defined as a cumulative dose of =/<444 mg food protein.
• No clinical reaction observed during the placebo (oat) challenge.
• Subject and/or parent guardian must be able to understand and provide informed consent.
• Written informed consent from adult participants.
• Written informed consent from parent/guardian for minor participants.
• Written assent from minor participants as appropriate (e.g., at and above the age of 7 years).
• Use of effective birth control by female participants of childbearing potential.

Exclusion Criteria:

• History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension.
• Individuals less than 15 kg in weight at start of the study
• History of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise or requiring intubation.
• History of chronic disease (other than asthma, atopic dermatitis or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen.
• History of eosinophilic esophagitis (EoE), another eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia (e.g., difficulty swallowing, food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology.
• Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
• Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if uncontrolled or difficult to control.

• Uncontrolled asthma as evidenced by:

  • FEV1 < 80% of predicted, or ratio of FEV1 to forced vital capacity (FEV1/FVC) < 75% of predicted, with or without controller medications (only for age 6 or greater and able to do spirometry reliably. If unable to do spirometry, PEF of >80% is acceptable) or;
  • One overnight admission to a hospital in the past year for asthma or;
  • Emergency room (ER) visit for asthma within six months prior to screening.
• Inability to tolerate biological (antibody) therapies.
• Use of immunomodulator therapy (not including corticosteroids).
• Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers.
• Current participation or within the last 4 months in any other interventional study.
• Pregnancy or lactation.
• Allergy to oat (placebo in DBPCFC).
• Use of investigational drugs within 16 weeks of participation.
• In build up phase of immunotherapy for aeroallergens or venom.

Contacts and Locations

Contacts

Contact: SNP Center Inquiry; 650-521-7237; snpcenterallergy_inquiry@stanford.edu

Locations

United States, California

University of California Los Angeles (UCLA); Recruiting

Los Angeles, California, United States, 90095

Contact: Stacey Zedeck, RN 310-794-5561 SSkura@mednet.ucla.edu

Principal Investigator: Maria Garcia-Lloret, MD

Sean N. Parker Center for Allergy & Asthma Research at Stanford University; Recruiting

Palo Alto, California, United States, 94304

Contact: SNP Center Inquiry 650-521-7237 snpcenterallergy_inquiry@stanford.edu

University of California San Diego (UCSD); Recruiting

San Diego, California, United States, 92123

Contact: Amy Grissinger, NP 858-966-5961 agrissinger@rchsd.org

Principal Investigator: Stephanie Leonard, MD

Sub-Investigator: Susan Laubach, MD

Sponsors and Collaborators

Stanford University

National Institute of Allergy and Infectious Diseases (NIAID)

Food Allergy Research & Education

Investigators

• Study Director: Rebecca S Chinthrajah, M.D.; Sean N Parker Center for Allergy and Asthma Center at Stanford

More Information

Additional Information:

Related Info 

• Responsible Party: R. Sharon Chinthrajah, Medical Director, Clinical Research Unit, Stanford University
• ClinicalTrials.gov Identifier: NCT03679676
• Other Study ID Numbers: IRB-47935; 5U19AI104209-07 ( U.S. NIH Grant/Contract )
• First Posted: September 20, 2018
• Last Update Posted: November 28, 2022
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by R. Sharon Chinthrajah, Stanford University:

Food Allergy; Hypersensitivity, Peanut; Food Hypersensitivity; Allergy, Food

Additional relevant MeSH terms:

Hypersensitivity; Food Hypersensitivity; Peanut Hypersensitivity; Immune System Diseases; Hypersensitivity, Immediate; Nut and Peanut Hypersensitivity; Omalizumab; Anti-Allergic Agents; Anti-Asthmatic Agents; Respiratory System Agents